TOP > 外国特許検索 > METHOD FOR SCREENING COMPOUND SPECIFICALLY INHIBITING FORMATION OF CAVEOLAE IN CANCER CELLS, SCREENING KIT, VECTOR AND TRANSFORMANT TO BE USED IN KIT, AND METHOD FOR SELECTING PATIENT ADAPTABLE FOR MOLECULAR-TARGETING DRUG

METHOD FOR SCREENING COMPOUND SPECIFICALLY INHIBITING FORMATION OF CAVEOLAE IN CANCER CELLS, SCREENING KIT, VECTOR AND TRANSFORMANT TO BE USED IN KIT, AND METHOD FOR SELECTING PATIENT ADAPTABLE FOR MOLECULAR-TARGETING DRUG

外国特許コード F160008824
整理番号 (S2015-0085-N0)
掲載日 2016年8月10日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2015JP075127
国際公開番号 WO 2016063637
国際出願日 平成27年9月3日(2015.9.3)
国際公開日 平成28年4月28日(2016.4.28)
優先権データ
  • 特願2014-217313 (2014.10.24) JP
発明の名称 (英語) METHOD FOR SCREENING COMPOUND SPECIFICALLY INHIBITING FORMATION OF CAVEOLAE IN CANCER CELLS, SCREENING KIT, VECTOR AND TRANSFORMANT TO BE USED IN KIT, AND METHOD FOR SELECTING PATIENT ADAPTABLE FOR MOLECULAR-TARGETING DRUG
発明の概要(英語) Provided is a method for screening a compound, said compound being capable of specifically inhibiting the formation of caveolae in cancer cells and comprehensively inhibiting various RTK activities only by the single compound. A screening method that is the method for screening a compound capable of specifically inhibiting the formation of caveolae in cancer cells, said screening method being characterized by comprising a step for contacting test compounds with a system capable of detecting the inhibition of the binding of Cavin-1 and CAV1, and a step for selecting a compound having an activity of inhibiting the binding of Cavin-1 and CAV1.
特許請求の範囲(英語) [claim1]
1. Being screening method of the chemical compound which controls the formation of [kabeora] of the cancer cell uniquely,
The aforementioned screening method,
The process which makes test chemical compound the system contact which can detect the control of the connection of Cavin-1 and CAV1,
The process which selects the chemical compound which possesses the activity which controls the connection of Cavin-1 and CAV1,
The screening method of featuring that it includes.
[claim2]
2. Can detect the control of connection description above Cavin-1 and CAV1 the system which,
In the claim 1 which features that it is the system which can detect the control of the function of Cavin-1 screening method of statement.
[claim3]
3. The system which can detect the control of function the description above Cavin-1, in the claim 2 which features that it is the system which can detect the control of connection with system or IGF-IR and Cavin-1 which can detect the control of the connection with ROR1 and Cavin-1 screening method of statement.
[claim4]
4. Can detect the control of connection description above Cavin-1 and CAV1 the system which,
In the claim 1 which features that it is the system which can detect the control of the function of CAV1 screening method of statement.
[claim5]
5. The system which can detect the control of function the description above CAV1, in the claim 4 which features that it is the system which can detect the control of connection with system or IGF-IR and CAV1 which can detect the control of the connection with ROR1 and CAV1 screening method of statement.
[claim6]
6. Among amino acid arrangement 428-937 turns of the cell inner territory of person ROR1, the rearrangement vector which inserts the nuclear acid which the amino acid arrangement which at least includes the amino acid territory of 564-746 turn the cord/code is done, and,
The rearrangement vector which inserts the nuclear acid which amino acid arrangement of person Cavin-1 the cord/code is done,
The transformant which is introduced.
[claim7]
7. The screening kit of the chemical compound which includes the transformant of statement in claim 6, controls the connection of ROR1 and Cavin-1.
[claim8]
8. Among amino acid arrangement 428-937 turns of the cell inner territory of person ROR1, the rearrangement vector which inserts the nuclear acid which the amino acid arrangement which at least includes the amino acid territory of 853-876 turn the cord/code is done, and,
The rearrangement vector which inserts the nuclear acid which amino acid arrangement of person CAV1 the cord/code is done,
The transformant which is introduced.
[claim9]
9. The screening kit of the chemical compound which includes the transformant of statement in claim 8, controls the connection of ROR1 and CAV1.
[claim10]
10. Among amino acid arrangement 428-937 turns of the cell inner territory of person ROR1, the nuclear acid which the amino acid arrangement which includes the amino acid territory of nuclear acid and the 853-876 turn which the amino acid arrangement which includes the amino acid territory of 564-746 turn the cord/code are done the cord/code is done, the rearrangement vector which is inserted at least,
The rearrangement vector which inserts the nuclear acid which amino acid arrangement of person Cavin-1 the cord/code is done, and,
The rearrangement vector which inserts the nuclear acid which amino acid arrangement of person CAV1 the cord/code is done,
The transformant which is introduced.
[claim11]
11. The chemical compound which includes the transformant of statement in claim 10, controls the connection of ROR1 and Cavin-1 and/or the screening kit of the chemical compound which controls the connection of ROR1 and CAV1.
[claim12]
12. Among amino acid arrangement 428-937 turns of the cell inner territory of person ROR1, the nuclear acid which the amino acid arrangement which includes the amino acid territory of 564-746 turn the cord/code is done and/or the nuclear acid which the amino acid arrangement which includes the amino acid territory of 853-876 turn the cord/code is done, the rearrangement vector which is inserted at least.
[claim13]
13. The process which acquires the cancer cell from the suffering inspection body,
The process which at least measures the revelation of 1 where it is selected, from ROR1 and Cavin-1, ROR1 and CAV1, IGF-IR and Cavin-1, IGF-IR and CAV1, Cavin-1 and CAV1, Cavin-1 or CAV1 in the aforementioned cancer cell kinds or more,
Selective method of the adaptation patient of the molecular target medicine which features that it includes.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NAGOYA UNIVERSITY
  • 発明者(英語)
  • TAKAHASHI TAKASHI
  • YAMAGUCHI TOMOYA
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
名古屋大学の公開特許情報を掲載しています。ご関心のある案件がございましたら、下記まで電子メールでご連絡ください。

PAGE TOP

close
close
close
close
close
close